Prevalence and pattern of adverse events following immunization to Covishield vaccine in a tertiary care hospital: a cross-sectional analytical study
Keywords:Vaccination, Covishield, COVID-19, Front line workers, AEFI
Background: The COVID-19 pandemic has emerged as the most important public health issue in the past two years. Multiple preventive and treatment modalities are being tried to contain this pandemic. Several countries have documented vaccines as a vital tool to combat this pandemic across the globe. Hence, we tried to evaluate the adverse events following immunisation at the study site following Covishield vaccination among front-line health workers in our tertiary care hospital.
Methods: A cross-sectional descriptive study was planned in the vaccination site of our institute, where all details of the frontline workers who were vaccinated for the Covishield vaccine were included, and they were followed up to study the prevalence and pattern of AEFIs. The participants were observed for 30 minutes after the jab and were reviewed/called upon on the third day following immunization to gather information. The data was collected using a semi-structured questionnaire
Results: Our study included around 159 frontline workers and medical students who received their vaccination during the study period. The mean age distribution was 24.3±7.6 years, with female predominance. We observed an AEFI prevalence of 33.3% among the study participants at the end of 30 minutes, while after 30 mins and during the next 3 days of follow-up by our staff, we observed that the prevalence increased to 80%. We observed that the commonest AEFI observed at 30 minutes and during the 3 days follow up was tenderness/pain, fever, body ache and light-headedness. Only 4% of the patients required hospitalisation following AEFI.
Conclusions: Around 1/3rd of our study participants reported AEFI following vaccination during the first 30 minutes of observation which is much higher than the national average.
WHO Coronavirus (COVID-19) dashboard. Available at: https:// covid19.who.int/. Accessed on 12 August 2022.
Coronavirus disease (COVID-190: Vaccine safety. Available at: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-(covid-19)- vaccines-safety. Accessed on 12 August 2022.
Draft landscape and tracker of COVID19 candidate vaccines. Available at: https://www.who.int/ publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed on 12 August 2022.
COVID-19 vaccines. Available at: https://www. who.int/emergencies/diseases/novel- coronavirus-2019/COVID-19- vaccines. Accessed on 12 August 2022.
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288: 198114.
Pandey SC, Pande V, Sati D, Upreti S, Samant M. Vaccination strategies to combat novel coronavirus SARS-CoV-2. Life Sci. 2020;256:117956.
Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. NPJ Vaccines. 2021;6(1):1-7.
Adverse Events Following Immunization (AEFI). Available at: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/ pharmacovigilance/health-professionals- info/aefi. Accessed on 12 August 2022.
Yadav SS. India’s Vaccine Growth Story. India: SAGE Publishing; 2022.
Joshi RK, Muralidharan CG, Gulati DS, Mopagar V, Dev JK, Kuthe S, et al. Higher incidence of reported adverse events following immunisation (AEFI) after the first dose of COVID-19 vaccine among previously infected health care workers. Med J Arm Forces India. 2021;77(2):S505.
Patil SP, Chavan SS, Kinge AD, Pagar VS. A study to determine adverse event following immunization using Covishield vaccine for prevention of COVID-19 infection in a field practice area of urban health center. Asian J Med Sci. 2022;13(6):1-6.
Krishnan A, Lekshmi A, Anusreeraj R, Dharan SS. Safety Surveillance of Covid-19 vaccine in tertiary care hospital among target population-an observational study. J Drug Del Ther. 2022;12(5):182-7.
Konda VC, Gokul T, Poojitha M, Rao KU. Adverse events following immunization to covid-19 vaccines in a tertiary care hospital a descriptive study. Biomed Pharmacol J. 2021;14(4):2149-56.
Subedi P, Yadav GK, Paudel B, Regmi A, Pyakurel P. Adverse events following the first dose of Covishield (ChAdOx1nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study. Plos One. 2021;16(12): e0260638.
Basavaraja CK, Sebastian J, Ravi MD and John SB. Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India. Ther Adv Vaccines Immunother. 2021;9:251.
CoWIN Dashboard. Available at: https://dashboard. cowin. gov.in. Accessed on 12 August 2022.
Lei J, Balakrishnan MR, Gidudu JF and Zuber PL. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015. Vaccine. 2018;36(12):1577-82.
Shrestha S, Devbhandari RP, Shrestha A, Aryal S, Rajbhandari P, Shakya B, et al. Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal. J Patan Acad Health Sci. 2021;8(1):9-17.
Rajpurohit P, Suva M, Rajpurohit H, Singh Y, Boda P. A retrospective observational survey of adverse events following immunization comparing tolerability of covishield and covaxin vaccines in the real world. J Pharmacovigil Drug Res. 2021;2(3):20-5.
Velhal GD, Kamath YV, Agrawal AS, Vora DS, Dwivedi VR. Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) vaccination: a prospctive study. Ind J Community Med. 2022;47(4):613-7.
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-49.
Nicola M, O'Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based management guideline for the COVID-19 pandemic Review article. Int J Surg. 2020;77:206-16.